Vijayakumar Narayanan*, Shane Ali Dungersi, James Mbogo
Historically, advanced and metastatic non-small cell lung cancer had dismal prognosis. These patients were subjected to best supportive care which included, inter alia, symptomatic management and advance care planning to get the best out of whatever time that is remaining for them. However, the past decade has seen important advances in treatment and diagnosis which have translated into improved survival outcomes in such cases. The Introduction of targeted therapy and immunotherapy for selected patients had dramatically changed the outcome of such patients, both in life expectancy and quality of life.
English 
Spanish 
Chinese 
Russian 
German 
Japanese 
Portuguese 
Hindi